We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Partnership with private sector aimed at cutting waiting lists amid spending constraints
Drugmaker does not specify reason but forex shortage has put pressure on multinationals
Legal and regulatory actions are more likely to drag on earnings than negate them
Novo Nordisk and Eli Lilly accused of failing to warn patients of gastroparesis risk
NHS backlogs targeted by expansion of centres for checks and scans
Chemify’s technology aims to remove bottleneck of producing molecules in the lab
Private equity’s unhealthy relationship with care
What the Britain’s Healthiest Workplace data tell us about the nation’s wellbeing, as tough economic times beckon. Also: counting the cost of rising long-term sickness on the economy; how organisations can tackle rising levels of exhaustion and retain staff; workspace designers are going all out on domesticity
Government pushes to increase capacity to meet rising demand
Adding hearing enhancement to the capabilities of earbuds and headphones would be smart if technology permits
Campaigners and experts welcome extra cash but warn of persistent staff shortages and need for wider reform
Drugmaker reports 38% jump in earnings as it expands genomic medicine business
After a dead-end job at a software company, Yoel Noorali took a job that surprised him in every way
Drugmaker projects rise in revenue of up to 10% after consensus-beating second quarter
New chief needs to signal to investors whether a restructuring is likely
Pharma industry deprioritising certain pills with shorter exclusivity period, says head of Swiss drugmaker
Roughly 68,000 hospital appointments and procedures axed because of last week’s walkout by senior doctors
Efforts by ProMED to raise money from public sector and philanthropists fall short of target
Providers warn of further closures because of rising costs and delay to promised reform
The more employers step into the area of supporting mental health, the more they open themselves up to claims that they are falling short
Technology veteran seen as critical in guiding Harrison.ai’s international growth in medical imaging
Promising trial results will not end scientific debate over the disease, but they further validate pharmaceutical research
Swiss drugmaker says potential deals not attractive enough to pursue
Dementia experts hail ‘watershed moment’ after trial results for donanemab antibody treatment
UK health security agency says low vaccination rates make capital vulnerable to a damaging outbreak
UK Edition